23 May 2013
Keywords: Europe, EMEA, Janssen-Cilag, Regranex, Johnson & Johnson, Cancer risk
Article | 19 February 2010
Following a review of the available data on a possible risk of cancer in patients using Regranex (becaplermin), from Janssen-Cilag ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 February 2010
18 February 2010
22 May 2013
© 2013 thepharmaletter.com